Legend Biotech Corporation
LEGN
$32.80
-$0.66-1.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 16.49% | -13.13% | |||
| Total Other Revenue | -20.28% | -88.40% | |||
| Total Revenue | 16.43% | -14.11% | |||
| Cost of Revenue | 18.12% | -7.41% | |||
| Gross Profit | -11.35% | -60.70% | |||
| SG&A Expenses | 4.47% | 21.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.41% | 0.91% | |||
| Operating Income | -6.54% | -67.63% | |||
| Income Before Tax | 133.51% | -572.71% | |||
| Income Tax Expenses | 220.79% | 1,862.39% | |||
| Earnings from Continuing Operations | 120.97% | -588.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 120.97% | -588.73% | |||
| EBIT | -6.54% | -67.63% | |||
| EBITDA | -6.00% | -73.45% | |||
| EPS Basic | 120.97% | -586.55% | |||
| Normalized Basic EPS | 137.17% | -570.24% | |||
| EPS Diluted | 120.97% | -583.80% | |||
| Normalized Diluted EPS | 133.82% | -570.24% | |||
| Average Basic Shares Outstanding | 0.02% | 0.37% | |||
| Average Diluted Shares Outstanding | 9.89% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||